CHRNA5 antibody

Product Graph
Contáctenos para saber el precio

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
CHRNA5 antibody
category
Primary Antibodies
provider
FineTest
reference
FNab01677
tested applications
ELISA, WB

Description

After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.

Documents del producto

Instrucciones
Descargar
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
cholinergic receptor, nicotinic, alpha 5 (CHRNA5)
Host
Rabbit
Reactivity
Human, Mouse, Rat
Recommended Dilution
WB: 1:500-1:2000
Clonality
polyclonal
Conjugation
Unconjugated
Isotype
IgG
Observed MW
53 kDa
Purity
≥95% as determined by SDS-PAGE
Purification
Immunogen affinity purified
Size 1
100µg
Form
liquid
Tested Applications
ELISA, WB
Storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
UniProt ID
P30532
Gene ID
1138
Alias
Neuronal acetylcholine receptor subunit alpha-5,CHRNA5,NACHRA5
Background
Antibody anti-CHRNA5
Status
RUO
Note
Mol. Weight 53 kDa

Descripción

Related Products

FNab01677

CHRNA5 antibody

After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.

Ver Producto
Pr22618

Recombinant Human NACHRA5

Ver Producto
abx001449

Cholinergic Receptor, Nicotinic Alpha 5 (CHRNA5) Antibody

CHRNA5 Antibody is a Rabbit Polyclonal antibody against CHRNA5. The protein encoded by this gene is a nicotinic acetylcholine receptor subunit and a member of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. These receptors are thought to be heteropentamers composed of separate but similar subunits. Defects in this gene have been linked to susceptibility to lung cancer type 2 (LNCR2).[provided by RefSeq, Jun 2010].

Ver Producto